Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer.

Journal of Thoracic Oncology（2020）

引用 215|浏览114

暂无评分

摘要

Neoadjuvant sintilimab was tolerable for NSCLC patients and 40.5% MPR rate is encouraging. The decrease of SUVmax after sintilimab might predict pathologic response.

查看译文

关键词

Neoadjuvant,NSCLC,PD-1 inhibitor,PD-L1 expression,SUVmax

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要